Business Description
Neuren Pharmaceuticals Ltd
NAICS : 541714
SIC : 2834
ISIN : NZNEUE0001S8
Total Employee Number:
37Description
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.98 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 365.54 | |||||
Beneish M-Score | -5.52 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 62.1 | |||||
3-Year EPS without NRI Growth Rate | 388.4 | |||||
3-Year FCF Growth Rate | 224.8 | |||||
3-Year Book Growth Rate | 102.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 37 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 44.43 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 20.48 | |||||
9-Day RSI | 41.11 | |||||
14-Day RSI | 52.63 | |||||
3-1 Month Momentum % | 21.21 | |||||
6-1 Month Momentum % | 30.72 | |||||
12-1 Month Momentum % | -0.99 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 46.45 | |||||
Quick Ratio | 46.45 | |||||
Cash Ratio | 39.91 | |||||
Days Sales Outstanding | 14.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward Dividend Yield % | 1.45 | |||||
3-Year Average Share Buyback Ratio | 0.6 | |||||
Shareholder Yield % | -0.11 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | 19.88 | |||||
Net Margin % | 29.14 | |||||
EBITDA Margin % | 19.92 | |||||
FCF Margin % | 7.88 | |||||
OCF Margin % | 7.94 | |||||
ROE % | 6.11 | |||||
ROA % | 5.99 | |||||
ROIC % | 26.94 | |||||
3-Year ROIIC % | 44.54 | |||||
ROC (Joel Greenblatt) % | 49.91 | |||||
ROCE % | 4.17 | |||||
Years of Profitability over Past 10-Year | 5 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 136.49 | |||||
Forward PE Ratio | 58.53 | |||||
PE Ratio without NRI | 136.49 | |||||
Shiller PE Ratio | 97.58 | |||||
Price-to-Owner-Earnings | 90.21 | |||||
PS Ratio | 39.36 | |||||
PB Ratio | 7.99 | |||||
Price-to-Tangible-Book | 7.99 | |||||
Price-to-Free-Cash-Flow | 512.68 | |||||
Price-to-Operating-Cash-Flow | 512.68 | |||||
EV-to-EBIT | 172.07 | |||||
EV-to-Forward-EBIT | 91.47 | |||||
EV-to-EBITDA | 171.75 | |||||
EV-to-Forward-EBITDA | 91.47 | |||||
EV-to-Revenue | 34.21 | |||||
EV-to-Forward-Revenue | 30.65 | |||||
EV-to-FCF | 468.44 | |||||
Price-to-GF-Value | 2.82 | |||||
Price-to-Projected-FCF | 4.28 | |||||
Price-to-Graham-Number | 6.98 | |||||
| Price-to-Net-Current-Asset-Value | 8.19 | |||||
| Price-to-Net-Cash | 9.55 | |||||
Earnings Yield (Greenblatt) % | 0.58 | |||||
FCF Yield % | 0.19 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Neuren Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 40.854 | ||
| EPS (TTM) (€) | 0.089 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 41.58 | ||
| 14-Day RSI | 52.63 | ||
| 14-Day ATR (€) | 0.384038 | ||
| 20-Day SMA (€) | 13.235 | ||
| 12-1 Month Momentum % | -0.99 | ||
| 52-Week Range (€) | 6.4 - 14.5 | ||
| Shares Outstanding (Mil) | 126.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Neuren Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Neuren Pharmaceuticals Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| AUD 0.150000 Cash Dividend | 2026-09-15 | In 17 days |
Show
Entries
Neuren Pharmaceuticals Ltd Frequently Asked Questions
What is Neuren Pharmaceuticals Ltd(FRA:NK9)'s stock price today?
The current price of FRA:NK9 is €12.70. The 52 week high of FRA:NK9 is €14.50 and 52 week low is €6.40.
When is next earnings date of Neuren Pharmaceuticals Ltd(FRA:NK9)?
The next earnings date of Neuren Pharmaceuticals Ltd(FRA:NK9) is .
Does Neuren Pharmaceuticals Ltd(FRA:NK9) pay dividends? If so, how much?
Neuren Pharmaceuticals Ltd(FRA:NK9) does not pay dividend.
Press Release
Articles on Neuren Pharmaceuticals Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers